Investment Thesis
Seres Therapeutics exhibits severe financial distress with minimal revenue of $358K, significant operating losses of $20.9M, and negative free cash flow of $16.4M annually, resulting in only ~1.8 years of cash runway. The company's 4.15x debt-to-equity ratio combined with $110M long-term debt creates elevated bankruptcy risk, with no clear path to profitability visible in current fundamentals.
Strengths
- Maintains positive cash balance of $29.8M providing near-term liquidity cushion
- Current ratio of 1.65x indicates ability to meet short-term obligations
- Active insider trading activity (9 Form 4 filings) suggests continued stakeholder engagement
Risks
- Extreme debt burden at 4.15x leverage with $110M long-term debt versus $26.5M equity
- Negative operating cash flow of $16.4M annually with limited runway at current burn rate
- Negligible revenue of $358K indicates failed commercialization or non-viable product pipeline
- Negative ROE (-75.1%) and ROA (-16.9%) demonstrate severe capital inefficiency
- Quick ratio of -1.09x signals potential liquidity crisis beyond current assets
Key Metrics to Watch
- Quarterly cash burn rate and remaining cash runway
- Revenue trajectory and product pipeline advancement
- Debt refinancing requirements and covenant compliance
- Operating cash flow trend toward breakeven
- Insider transaction patterns indicating confidence or exits
Financial Metrics
Revenue
358.0K
Net Income
-19.9M
EPS (Diluted)
$-2.08
Free Cash Flow
-16.4M
Total Assets
117.6M
Cash
29.8M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-5,839.9%
Net Margin
-5,562.3%
ROE
-75.1%
ROA
-16.9%
FCF Margin
-4,569.8%
Balance Sheet & Liquidity
Current Ratio
1.65x
Quick Ratio
-1.09x
Debt/Equity
4.15x
Debt/Assets
77.5%
Interest Coverage
N/A
Long-term Debt
110.0M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-08T11:12:48.084346 |
Data as of: 2026-03-31 |
Powered by Claude AI